Early Chemotherapy in Metastatic Prostate Cancer Improves Survival: a Quick Note to Surgical Colleagues

Autor:	Ajit Venniyoor, Itrat Mehdi, Rajan Balakrishnan, Bassim Al Bahrani
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Cancer Disease medicine.disease 03 medical and health sciences Prostate cancer 0302 clinical medicine Cardiothoracic surgery 030220 oncology & carcinogenesis Internal medicine Pediatric surgery medicine Hormonal therapy 030211 gastroenterology & hepatology Surgery Neurosurgery business
Zdroj:	Indian Journal of Surgery. 82:1206-1211
ISSN:	0973-9793 0972-2068
Popis:	Metastatic prostate cancer is a hormone sensitive cancer. For patients with prostate cancer, general surgeons and urologists are the points of first contact. Historically, restricted treatment options meant that such patients were started on, and continued hormonal therapy with them. Chemotherapy is started once these tumours became hormone-refractory, with limited survival benefits. However, three recently published randomized, Phase III trials (GETUG-AFU15, CHAARTED, STAMPEDE) have provided Level I evidence that upfront chemotherapy in hormone sensitive metastatic prostate cancer dramatically improves survival, especially in those with heavy volume disease (an increase of up to 22 months). The authors recommend that general surgeons and urologists discuss patients in multi-disciplinary tumour boards so that fit patients can receive the benefits of upfront chemotherapy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::363ac885f0568daa0582c378c44793e0 https://doi.org/10.1007/s12262-020-02213-y Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.